Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Official Title
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
Quick Facts
Study Start:2025-05-20
Study Completion:2032-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136-1002
United States
Florida Cancer Specialists
Sarasota, Florida, 34232-6422
United States
The Emory Clinic
Atlanta, Georgia, 30322-1013
United States
Northwestern University
Chicago, Illinois, 60611-3013
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Mayo Clinic- Minnesota
Rochester, Minnesota, 55905
United States
University Of Nebraska Medical Center
Omaha, Nebraska, 69198
United States
Cayuga Cancer Center
Ithaca, New York, 14850
United States
Northwell Health
Lake Success, New York, 11042-1118
United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, 10065-6007
United States
Duke University Medical Center
Durham, North Carolina, 27710-4000
United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210-1063
United States
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104
United States
Tennessee Oncology
Nashville, Tennessee, 37203-2659
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
United States
Swedish Cancer Institute
Seattle, Washington, 98104-3588
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226-3548
United States
Collaborators and Investigators
Sponsor: Eli Lilly and Company
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2025-05-20
Study Completion Date2032-12
Study Record Updates
Study Start Date2025-05-20
Study Completion Date2032-12
Terms related to this study
Additional Relevant MeSH Terms
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma